Contact
searchSearch
HMP Global
Login

Colorectal Cancer Resource Center

Featured

Special Report
Navigating the Management of Metastatic Colorectal Cancer in the Advanced Treatment Setting: Insights From an Expert Panel
08/15/2025
Tanios Bekaii-Saab, MD, FACP; Stacey Cohen, MD; Marwan Fakih, MD; Anwaar Saeed, MD
Review a special report on the current treatment landscape and unmet needs in metastatic colorectal cancer (mCRC).
Review a special report on the current treatment landscape and unmet needs in metastatic colorectal cancer (mCRC).
Review a special report on the...
08/15/2025
Journal of Clinical Pathways
Jeanne Tie, MBChB, MD, Peter MacCallum Cancer Centre
Videos
Circulating Tumor DNA-Guided vs Standard Management of Locally Advanced Rectal Cancer
01/20/2024
Jeanne Tie, MBChB, MD
Professor Jeanne Tie, MBChB, FRACP, MD, discusses results from the AGITG DYNAMIC-Rectal study, which explored a ctDNA-guided approach to adjuvant chemotherapy following neoadjuvant chemoradiation for locally advanced rectal cancer.
Professor Jeanne Tie, MBChB, FRACP, MD, discusses results from the AGITG DYNAMIC-Rectal study, which explored a ctDNA-guided approach to adjuvant chemotherapy following neoadjuvant chemoradiation for locally advanced rectal cancer.
Professor Jeanne Tie, MBChB,...
01/20/2024
Oncology
From Oncology
Conference Coverage
Significance of ctDNA Clearance Following Adjuvant Chemotherapy Among Patients with Radically Resected Colorectal Cancer
01/20/2024
Allison Casey
According to updated results from a substudy of the observational GALAXY study, detection of MRD via ctDNA and ctDNA dynamics in response to adjuvant chemotherapy for colorectal cancer were found to be highly prognostic of patient outcomes in...
According to updated results from a substudy of the observational GALAXY study, detection of MRD via ctDNA and ctDNA dynamics in response to adjuvant chemotherapy for colorectal cancer were found to be highly prognostic of patient outcomes in...
According to updated results...
01/20/2024
Oncology
From Oncology
Conference Coverage
Role of ctDNA to Guide Adjuvant Chemotherapy Use for Patients With Colon Cancer
01/20/2024
Allison Casey
In the phase 2/3 COBRA study no improvement in ctDNA clearance was observed after 6 months of chemotherapy among patients with ctDNA detected following resection of stage IIA colon cancer.
In the phase 2/3 COBRA study no improvement in ctDNA clearance was observed after 6 months of chemotherapy among patients with ctDNA detected following resection of stage IIA colon cancer.
In the phase 2/3 COBRA study no...
01/20/2024
Oncology
From Oncology
Kristin Savill, PhD
Videos
Evaluating Real-World Utilization of ctDNA Testing in the Management of Patients With Colorectal Cancer
06/30/2022
Kristin Savill, PhD, discusses her survey-based study that evaluated the utilization of circulating tumor DNA testing in the management of colorectal cancer among practicing community oncologists in the US.
Kristin Savill, PhD, discusses her survey-based study that evaluated the utilization of circulating tumor DNA testing in the management of colorectal cancer among practicing community oncologists in the US.
Kristin Savill, PhD, discusses...
06/30/2022
Journal of Clinical Pathways
News
Bevacizumab-bvzr Biosimilar Used Most Frequently for Metastatic Colorectal Cancer in US Oncology Practice, According to Retrospective Cohort Study
06/09/2022
Ellen Kurek
This study finds that US oncologists have adopted switching between the bevacizumab reference product and bevacizumab biosimilars as well as using bevacizumab-bvzr in chemotherapy combination regimens.
This study finds that US oncologists have adopted switching between the bevacizumab reference product and bevacizumab biosimilars as well as using bevacizumab-bvzr in chemotherapy combination regimens.
This study finds that US...
06/09/2022
Journal of Clinical Pathways
Conference Coverage
Bevacizumab-awwb Safe, Effective Among Patients With Metastatic Colorectal Cancer
06/04/2022
Robert Fee
Study examines real-world effectiveness and safety of Bevacizumab-awwb, the first FDA-approved biosimilar to Avastin, among patients with metastatic colorectal cancer.
Study examines real-world effectiveness and safety of Bevacizumab-awwb, the first FDA-approved biosimilar to Avastin, among patients with metastatic colorectal cancer.
Study examines real-world...
06/04/2022
Journal of Clinical Pathways
John Strickler, MD
Videos
Real-World Treatment Patterns Among Patients With HER2-Amplified Metastatic Colorectal Cancer
03/17/2022
John Strickler, MD, discusses real-world treatment patterns in patients with HER2 amplified metastatic colorectal cancer in the United States—analyzing how treatment patterns changed before 2018 and after 2018.
John Strickler, MD, discusses real-world treatment patterns in patients with HER2 amplified metastatic colorectal cancer in the United States—analyzing how treatment patterns changed before 2018 and after 2018.
John Strickler, MD, discusses...
03/17/2022
Journal of Clinical Pathways
Quiz
Quiz: Cost-Effectiveness of Doublet Therapy for Colorectal Cancer
04/13/2021
04/13/2021
Journal of Clinical Pathways
Videos
HRQoL Low Among Young Adult Colorectal Cancer Survivors
02/04/2021
Kimberly Miller, PhD, MPH, discusses results from a study exploring HRQoL in colorectal cancer survivors who were diagnosed before age 50.
Kimberly Miller, PhD, MPH, discusses results from a study exploring HRQoL in colorectal cancer survivors who were diagnosed before age 50.
Kimberly Miller, PhD, MPH,...
02/04/2021
Journal of Clinical Pathways
ENGAGING EXPERTS
NCCN Guideline Adherence Improves Survival Outcomes in Anal Cancer
02/03/2021
02/03/2021
Journal of Clinical Pathways

Expert Insights

Jeanne Tie, MBChB, MD, Peter MacCallum Cancer Centre
Videos
Circulating Tumor DNA-Guided vs Standard Management of Locally Advanced Rectal Cancer
01/20/2024
Jeanne Tie, MBChB, MD
Professor Jeanne Tie, MBChB, FRACP, MD, discusses results from the AGITG DYNAMIC-Rectal study, which explored a ctDNA-guided approach to adjuvant chemotherapy following neoadjuvant chemoradiation for locally advanced rectal cancer.
Professor Jeanne Tie, MBChB, FRACP, MD, discusses results from the AGITG DYNAMIC-Rectal study, which explored a ctDNA-guided approach to adjuvant chemotherapy following neoadjuvant chemoradiation for locally advanced rectal cancer.
Professor Jeanne Tie, MBChB,...
01/20/2024
Oncology
Kristin Savill, PhD
Videos
Evaluating Real-World Utilization of ctDNA Testing in the Management of Patients With Colorectal Cancer
06/30/2022
Kristin Savill, PhD, discusses her survey-based study that evaluated the utilization of circulating tumor DNA testing in the management of colorectal cancer among practicing community oncologists in the US.
Kristin Savill, PhD, discusses her survey-based study that evaluated the utilization of circulating tumor DNA testing in the management of colorectal cancer among practicing community oncologists in the US.
Kristin Savill, PhD, discusses...
06/30/2022
Journal of Clinical Pathways
John Strickler, MD
Videos
Real-World Treatment Patterns Among Patients With HER2-Amplified Metastatic Colorectal Cancer
03/17/2022
John Strickler, MD, discusses real-world treatment patterns in patients with HER2 amplified metastatic colorectal cancer in the United States—analyzing how treatment patterns changed before 2018 and after 2018.
John Strickler, MD, discusses real-world treatment patterns in patients with HER2 amplified metastatic colorectal cancer in the United States—analyzing how treatment patterns changed before 2018 and after 2018.
John Strickler, MD, discusses...
03/17/2022
Journal of Clinical Pathways
Videos
HRQoL Low Among Young Adult Colorectal Cancer Survivors
02/04/2021
Kimberly Miller, PhD, MPH, discusses results from a study exploring HRQoL in colorectal cancer survivors who were diagnosed before age 50.
Kimberly Miller, PhD, MPH, discusses results from a study exploring HRQoL in colorectal cancer survivors who were diagnosed before age 50.
Kimberly Miller, PhD, MPH,...
02/04/2021
Journal of Clinical Pathways
ENGAGING EXPERTS
NCCN Guideline Adherence Improves Survival Outcomes in Anal Cancer
02/03/2021
02/03/2021
Journal of Clinical Pathways
Woyach Headshot
Interview
Targeting BTK Mutations in CLL: Emerging Data on Rocbrutinib
12/18/2025
Jennifer Ann Woyach, MD
This interview highlights early clinical findings on rocbrutinib, a dual-binding BTK inhibitor demonstrating promising activity and tolerability in heavily pretreated CLL, including in the presence of common resistance mutations.
This interview highlights early clinical findings on rocbrutinib, a dual-binding BTK inhibitor demonstrating promising activity and tolerability in heavily pretreated CLL, including in the presence of common resistance mutations.
This interview highlights early...
12/18/2025
Journal of Clinical Pathways
Joanna Rhodes, MD, MSCE
Interview
Transforming CLL Management: How MRD Could Shape Treatment Duration and Decision-Making
12/17/2025
In this candid discussion, Joanna Rhodes, MD, MSCE, breaks down the promise and current limitations of MRD testing in chronic lymphocytic leukemia (CLL), exploring how it could one day refine treatment intensity, timing, and outcomes, and...
In this candid discussion, Joanna Rhodes, MD, MSCE, breaks down the promise and current limitations of MRD testing in chronic lymphocytic leukemia (CLL), exploring how it could one day refine treatment intensity, timing, and outcomes, and...
In this candid discussion,...
12/17/2025
Journal of Clinical Pathways
ONLINE EXCLUSIVES
Medicare and Cancer Care Reform: Closing the Gaps in Access and Affordability
12/15/2025
Youngmin Kwon
In this interview, postdoctoral fellow Youngmin Kwon, PhD, discusses recent health care reforms and reveals how bold policy shifts are finally helping to close long-standing gaps in cancer-care access and affordability.
In this interview, postdoctoral fellow Youngmin Kwon, PhD, discusses recent health care reforms and reveals how bold policy shifts are finally helping to close long-standing gaps in cancer-care access and affordability.
In this interview, postdoctoral...
12/15/2025
Journal of Clinical Pathways
Houda Hachad, PharmD
Videos
Clinical Implications of the FDA’s Capecitabine Boxed Warning: Integrating DPYD Testing into Oncology Practice: Part 2
12/04/2025
Houda Hachad, PharmD
Houda Hachad, PharmD, discusses how emerging US Food and Drug Administration (FDA) actions and expanding pharmacogenomic insights may soon transform fluoropyrimidine safety and reshape precision oncology from diagnosis through survivorship.
Houda Hachad, PharmD, discusses how emerging US Food and Drug Administration (FDA) actions and expanding pharmacogenomic insights may soon transform fluoropyrimidine safety and reshape precision oncology from diagnosis through survivorship.
Houda Hachad, PharmD, discusses...
12/04/2025
Journal of Clinical Pathways
Houda Hachad, PharmD
Videos
Clinical Implications of the FDA’s Capecitabine Boxed Warning: Integrating DPYD Testing into Oncology Practice
12/04/2025
Houda Hachad, PharmD
Learn why mandatory DPYD testing may be just the beginning of a broader shift toward pharmacogenomics-driven safety in cancer treatment.
Learn why mandatory DPYD testing may be just the beginning of a broader shift toward pharmacogenomics-driven safety in cancer treatment.
Learn why mandatory DPYD testing...
12/04/2025
Journal of Clinical Pathways
BDHC thumbnail
Videos
Breaking Down Cancer Prevention: What Really Works?
11/26/2025
John Hennessy, MBA; Michael Kolodziej, MD
In this episode of Breaking Down Health Care, John Hennessy and Dr. Michael Kolodziej explore the crucial difference between cancer screening and true cancer prevention, highlighting how lifestyle changes, vaccines, and emerging therapies...
In this episode of Breaking Down Health Care, John Hennessy and Dr. Michael Kolodziej explore the crucial difference between cancer screening and true cancer prevention, highlighting how lifestyle changes, vaccines, and emerging therapies...
In this episode of Breaking Down...
11/26/2025
Cancer Care Business Exchange
Koulopoulos
Videos
Gigatrends Reshaping Global Health Care: Insights for CPC+CBEx 2025
10/31/2025
Thomas Koulopoulos
Futurist Thomas Koulopoulos explores how “gigatrends”—seismic global shifts like changing demographics and AI—are redefining health care, urging a balance between innovation and trust as the industry evolves toward more human-centered,...
Futurist Thomas Koulopoulos explores how “gigatrends”—seismic global shifts like changing demographics and AI—are redefining health care, urging a balance between innovation and trust as the industry evolves toward more human-centered,...
Futurist Thomas Koulopoulos...
10/31/2025
Journal of Clinical Pathways
Kwon Headshot
Interview
Medicare and Cancer Care Reform: Closing the Gaps in Access and Affordability
10/23/2025
Postdoctoral fellow Youngmin Kwon discusses how Medicare eligibility reduces financial barriers for cancer survivors, and why disparities in access and affordability still persist.
Postdoctoral fellow Youngmin Kwon discusses how Medicare eligibility reduces financial barriers for cancer survivors, and why disparities in access and affordability still persist.
Postdoctoral fellow Youngmin...
10/23/2025
Journal of Clinical Pathways
CONFERENCE COVERAGE
CAR T-Cell Therapy and Bispecifics in the Community: Opportunities and Obstacles
10/22/2025
Lavi Kwiatkowsky
At CPC+CBEx 2025, Lavi Kwiatkowsky discussed how payer frameworks, accreditation requirements, and operational challenges are shaping access to CAR T-cell and bispecific therapies in community oncology—and how technology could bridge the gap...
At CPC+CBEx 2025, Lavi Kwiatkowsky discussed how payer frameworks, accreditation requirements, and operational challenges are shaping access to CAR T-cell and bispecific therapies in community oncology—and how technology could bridge the gap...
At CPC+CBEx 2025, Lavi...
10/22/2025
Journal of Clinical Pathways
Gilmore
Interview
Pharmacy-Driven Pathways: Enhancing Efficacy, Tolerability, and Value in Oncology Care
10/17/2025
James Gilmore, PharmD
At CPC+CBEx 2025, James Gilmore, PharmD, discussed how the American Oncology Network is elevating pharmacist-driven clinical pathways through data, technology, and collaboration to advance value-based care and enhance patient safety with...
At CPC+CBEx 2025, James Gilmore, PharmD, discussed how the American Oncology Network is elevating pharmacist-driven clinical pathways through data, technology, and collaboration to advance value-based care and enhance patient safety with...
At CPC+CBEx 2025, James Gilmore,...
10/17/2025
Journal of Clinical Pathways

Newsfeed

Jeanne Tie, MBChB, MD, Peter MacCallum Cancer Centre
Videos
Circulating Tumor DNA-Guided vs Standard Management of Locally Advanced Rectal Cancer
01/20/2024
Jeanne Tie, MBChB, MD
Professor Jeanne Tie, MBChB, FRACP, MD, discusses results from the AGITG DYNAMIC-Rectal study, which explored a ctDNA-guided approach to adjuvant chemotherapy following neoadjuvant chemoradiation for locally advanced rectal cancer.
Professor Jeanne Tie, MBChB, FRACP, MD, discusses results from the AGITG DYNAMIC-Rectal study, which explored a ctDNA-guided approach to adjuvant chemotherapy following neoadjuvant chemoradiation for locally advanced rectal cancer.
Professor Jeanne Tie, MBChB,...
01/20/2024
Oncology
Conference Coverage
Significance of ctDNA Clearance Following Adjuvant Chemotherapy Among Patients with Radically Resected Colorectal Cancer
01/20/2024
Allison Casey
According to updated results from a substudy of the observational GALAXY study, detection of MRD via ctDNA and ctDNA dynamics in response to adjuvant chemotherapy for colorectal cancer were found to be highly prognostic of patient outcomes in...
According to updated results from a substudy of the observational GALAXY study, detection of MRD via ctDNA and ctDNA dynamics in response to adjuvant chemotherapy for colorectal cancer were found to be highly prognostic of patient outcomes in...
According to updated results...
01/20/2024
Oncology
Conference Coverage
Role of ctDNA to Guide Adjuvant Chemotherapy Use for Patients With Colon Cancer
01/20/2024
Allison Casey
In the phase 2/3 COBRA study no improvement in ctDNA clearance was observed after 6 months of chemotherapy among patients with ctDNA detected following resection of stage IIA colon cancer.
In the phase 2/3 COBRA study no improvement in ctDNA clearance was observed after 6 months of chemotherapy among patients with ctDNA detected following resection of stage IIA colon cancer.
In the phase 2/3 COBRA study no...
01/20/2024
Oncology
News
Bevacizumab-bvzr Biosimilar Used Most Frequently for Metastatic Colorectal Cancer in US Oncology Practice, According to Retrospective Cohort Study
06/09/2022
Ellen Kurek
This study finds that US oncologists have adopted switching between the bevacizumab reference product and bevacizumab biosimilars as well as using bevacizumab-bvzr in chemotherapy combination regimens.
This study finds that US oncologists have adopted switching between the bevacizumab reference product and bevacizumab biosimilars as well as using bevacizumab-bvzr in chemotherapy combination regimens.
This study finds that US...
06/09/2022
Journal of Clinical Pathways
Conference Coverage
Bevacizumab-awwb Safe, Effective Among Patients With Metastatic Colorectal Cancer
06/04/2022
Robert Fee
Study examines real-world effectiveness and safety of Bevacizumab-awwb, the first FDA-approved biosimilar to Avastin, among patients with metastatic colorectal cancer.
Study examines real-world effectiveness and safety of Bevacizumab-awwb, the first FDA-approved biosimilar to Avastin, among patients with metastatic colorectal cancer.
Study examines real-world...
06/04/2022
Journal of Clinical Pathways
Conference Coverage
Tumor Mutation Burden Unlikely Biomarker for Checkpoint Inhibitor Response in CRC
02/03/2021
02/03/2021
Journal of Clinical Pathways
News
2025 US Cancer Disparities Report Highlights Education, Rural Gaps
01/12/2026
Hannah Musick
The American Cancer Society’s 2025 report reveals that education level and rural residence drive larger US cancer mortality disparities than race alone, underscoring the central role of socioeconomic and geographic inequities across the...
The American Cancer Society’s 2025 report reveals that education level and rural residence drive larger US cancer mortality disparities than race alone, underscoring the central role of socioeconomic and geographic inequities across the...
The American Cancer Society’s...
01/12/2026
Journal of Clinical Pathways
News
Real-World Data Show Similar Outcomes for First-Line uHCC Immunotherapy Regimens
01/08/2026
Grace Taylor, MS, MA
Real-world data from 6 US cancer centers show no significant survival differences between atezolizumab/bevacizumab and durvalumab/tremelimumab as first-line therapy for unresectable hepatocellular carcinoma (uHCC), with liver function...
Real-world data from 6 US cancer centers show no significant survival differences between atezolizumab/bevacizumab and durvalumab/tremelimumab as first-line therapy for unresectable hepatocellular carcinoma (uHCC), with liver function...
Real-world data from 6 US cancer...
01/08/2026
Journal of Clinical Pathways
News
CAR T Therapy Access Remains Uneven Despite Specialist Referral
01/07/2026
Grace Taylor, MS, MA
Nearly half of patients referred for chimeric antigen receptor T-cell (CAR T) therapy at a major academic cancer center never received treatment, with disease progression, limited product availability, and potential racial disparities...
Nearly half of patients referred for chimeric antigen receptor T-cell (CAR T) therapy at a major academic cancer center never received treatment, with disease progression, limited product availability, and potential racial disparities...
Nearly half of patients referred...
01/07/2026
Journal of Clinical Pathways
Conference Coverage
Daratumumab Maintenance Deepens MRD Negativity After ASCT in Multiple Myeloma
12/22/2025
Juliet Gallagher
Minimal residual disease (MRD) status is an increasingly important prognostic marker in multiple myeloma. New data from the phase 3 AURIGA study, presented at ASH 2025, provide detailed insights into MRD dynamics following autologous stem...
Minimal residual disease (MRD) status is an increasingly important prognostic marker in multiple myeloma. New data from the phase 3 AURIGA study, presented at ASH 2025, provide detailed insights into MRD dynamics following autologous stem...
Minimal residual disease (MRD)...
12/22/2025
Journal of Clinical Pathways
Conference Coverage
Biology-Based Strategies for Managing Iron Toxicity in Hematologic Disorders
12/19/2025
Grace Taylor, MS, MA
New insights into iron biology reveal that continuous suppression of toxic, reactive iron—rather than reduction of total iron stores—is critical for preventing organ damage and improving outcomes across transfusion-dependent hematologic...
New insights into iron biology reveal that continuous suppression of toxic, reactive iron—rather than reduction of total iron stores—is critical for preventing organ damage and improving outcomes across transfusion-dependent hematologic...
New insights into iron biology...
12/19/2025
Journal of Clinical Pathways
News
Lenalidomide Before Apheresis Enhances CAR T-Cell Fitness in Newly Diagnosed Multiple Myeloma
12/19/2025
Grace Taylor, MS, MA
Pre-apheresis lenalidomide significantly improved T-cell fitness and pharmacodynamic activity of idecabtagene vicleucel (ide-cel) in newly diagnosed multiple myeloma (NDMM), according to a KarMMa-2 cross-cohort analysis.
Pre-apheresis lenalidomide significantly improved T-cell fitness and pharmacodynamic activity of idecabtagene vicleucel (ide-cel) in newly diagnosed multiple myeloma (NDMM), according to a KarMMa-2 cross-cohort analysis.
Pre-apheresis lenalidomide...
12/19/2025
Journal of Clinical Pathways
Conference Coverage
High-Risk Features Predict Early Relapse After Cilta-Cel Therapy in Relapsed/Refractory Multiple Myeloma
12/18/2025
Grace Taylor, MS, MA
Cilta-cel continues to deliver high response rates in RRMM, yet early relapse remains a critical challenge. A multicenter analysis across 15 US academic institutions evaluated high-risk disease biology to identify predictors of suboptimal...
Cilta-cel continues to deliver high response rates in RRMM, yet early relapse remains a critical challenge. A multicenter analysis across 15 US academic institutions evaluated high-risk disease biology to identify predictors of suboptimal...
Cilta-cel continues to deliver...
12/18/2025
Journal of Clinical Pathways
Conference Coverage
Intensive Isa-VRDc Regimen Shows Strong Progression-Free Survival in Double-Hit Myeloma
12/17/2025
Hannah Musick
An intensified Isa-VRDc regimen achieved an 88% 18-month progression-free survival rate in newly diagnosed, double-hit multiple myeloma patients in the UK RADAR trial, signaling strong early efficacy in this ultra-high-risk population.
An intensified Isa-VRDc regimen achieved an 88% 18-month progression-free survival rate in newly diagnosed, double-hit multiple myeloma patients in the UK RADAR trial, signaling strong early efficacy in this ultra-high-risk population.
An intensified Isa-VRDc regimen...
12/17/2025
Journal of Clinical Pathways
Conference Coverage
Breakthrough Advances in Immunotherapy Transform Care in Leukemia, Lymphoma, and Myeloma
12/17/2025
Grace Taylor, MS, MA
Immunotherapy advancements across leukemia, lymphoma, and myeloma are reshaping treatment pathways, demonstrating deeper responses, improved survival, and expanding earlier-line options for patients.
Immunotherapy advancements across leukemia, lymphoma, and myeloma are reshaping treatment pathways, demonstrating deeper responses, improved survival, and expanding earlier-line options for patients.
Immunotherapy advancements...
12/17/2025
Journal of Clinical Pathways
Conference Coverage
Advances in Molecular Diagnostics Transform Care for Cytopenias and Hereditary Anemias
12/16/2025
Grace Taylor, MS, MA
Emerging molecular diagnostics are redefining how clinicians evaluate cytopenias, bone marrow failure, and hereditary anemias, enabling more accurate diagnoses and better-informed treatment decisions.
Emerging molecular diagnostics are redefining how clinicians evaluate cytopenias, bone marrow failure, and hereditary anemias, enabling more accurate diagnoses and better-informed treatment decisions.
Emerging molecular diagnostics...
12/16/2025
Journal of Clinical Pathways

Interactive Features

Quiz
Quiz: Cost-Effectiveness of Doublet Therapy for Colorectal Cancer
04/13/2021
04/13/2021
Journal of Clinical Pathways
Quiz
Regional Inequalities Persist in Lung Cancer Mortality Trends
11/19/2025
11/19/2025
Journal of Clinical Pathways
Quiz
Rural Health Transformation Program Fund Distribution
09/29/2025
True or False: The Rural Health Transformation Program, announced by CMS under the Working Families Tax Cuts Act, will allocate $50 billion beginning in fiscal year 2026, with funding distributed evenly across all states regardless of...
True or False: The Rural Health Transformation Program, announced by CMS under the Working Families Tax Cuts Act, will allocate $50 billion beginning in fiscal year 2026, with funding distributed evenly across all states regardless of...
True or False: The Rural Health...
09/29/2025
Journal of Clinical Pathways
Quiz
Uncovering the True Cost of Care
09/18/2025
Learn more about the Predictable Cost of Care (PCOC) model and its applications in value-based care.
Learn more about the Predictable Cost of Care (PCOC) model and its applications in value-based care.
Learn more about the Predictable...
09/18/2025
Journal of Clinical Pathways
Quiz
Understanding the NCCN Guidelines Navigator
08/27/2025
The National Comprehensive Cancer Network (NCCN) Guidelines Navigator is a new interactive digital platform that delivers evidence-based oncology recommendations and is currently available for all 88 NCCN guideline sets.
The National Comprehensive Cancer Network (NCCN) Guidelines Navigator is a new interactive digital platform that delivers evidence-based oncology recommendations and is currently available for all 88 NCCN guideline sets.
The National Comprehensive...
08/27/2025
Journal of Clinical Pathways
Quiz
Specialty Palliative Care Trends for Medicare Beneficiaries
08/12/2025
Between 2018 and 2023, which of the following trends was observed in the delivery of specialty palliative care (PC) among Medicare beneficiaries with poor-prognosis cancers?
Between 2018 and 2023, which of the following trends was observed in the delivery of specialty palliative care (PC) among Medicare beneficiaries with poor-prognosis cancers?
Between 2018 and 2023, which of...
08/12/2025
Journal of Clinical Pathways
Quiz
Understanding the Role of Clinical Pathways in Oncology Care
07/30/2025
Learn more about how clinical pathways are helping multidisciplinary teams standardize cancer care, reduce costs, and improve outcomes—and why aligning them with evidence-based guidelines is essential in today’s value-based healthcare...
Learn more about how clinical pathways are helping multidisciplinary teams standardize cancer care, reduce costs, and improve outcomes—and why aligning them with evidence-based guidelines is essential in today’s value-based healthcare...
Learn more about how clinical...
07/30/2025
Journal of Clinical Pathways
SPONSORED QUIZ BY SANOFI
Treatments in Multiple Myeloma
11/28/2022
  Indication SARCLISA (isatuximab-irfc) is indicated: In combination with carfilzomib and dexamethasone, for the treatment of adult patients with relapsed or refractory multiple myeloma who have received 1 to 3 prior lines of...
  Indication SARCLISA (isatuximab-irfc) is indicated: In combination with carfilzomib and dexamethasone, for the treatment of adult patients with relapsed or refractory multiple myeloma who have received 1 to 3 prior lines of...
  Indication SARCLISA...
11/28/2022
Journal of Clinical Pathways
Quiz
Quiz: Medicaid Insurance and Biomarker Testing in NSCLC
07/26/2022
True or False: Medicaid beneficiaries with advanced non-small cell lung cancer were less likely to receive biomarker testing and biomarker-driven therapies compared to those with commercial insurance.
True or False: Medicaid beneficiaries with advanced non-small cell lung cancer were less likely to receive biomarker testing and biomarker-driven therapies compared to those with commercial insurance.
True or False: Medicaid...
07/26/2022
Journal of Clinical Pathways
Quiz
Quiz: Comparing the Cost of Regimens in Newly Diagnosed Multiple Myeloma
07/14/2022
True or False: Among daratumumab, lenalidomide, and dexamethasone triple therapy (DRd); bortezomib and lenalidomide plus dexamethasone triple therapy (VRd); and Rd, the most cost-effective treatment regimen in patients with newly diagnosed...
True or False: Among daratumumab, lenalidomide, and dexamethasone triple therapy (DRd); bortezomib and lenalidomide plus dexamethasone triple therapy (VRd); and Rd, the most cost-effective treatment regimen in patients with newly diagnosed...
True or False: Among...
07/14/2022
Journal of Clinical Pathways
Quiz
Quiz: Germline BRCA Testing in Ovarian Cancer
07/12/2022
True or False: About 34% of commercially insured patients with ovarian cancer receive germline BRCA testing.
True or False: About 34% of commercially insured patients with ovarian cancer receive germline BRCA testing.
True or False: About 34% of...
07/12/2022
Journal of Clinical Pathways
JCP Nov-Dec Cover

Current Issue

December 2025
Volume 11
Issue 6
Current Issue
Issue Archive

Special Reports

Special Report
Navigating the Management of Metastatic Colorectal Cancer in the Advanced Treatment Setting: Insights From an Expert Panel
08/15/2025
Tanios Bekaii-Saab, MD, FACP; Stacey Cohen, MD; Marwan Fakih, MD; Anwaar Saeed, MD
Review a special report on the current treatment landscape and unmet needs in metastatic colorectal cancer (mCRC).
Review a special report on the current treatment landscape and unmet needs in metastatic colorectal cancer (mCRC).
Review a special report on the...
08/15/2025
Journal of Clinical Pathways
Special Report
Navigating the Management of Metastatic Colorectal Cancer in the Advanced Treatment Setting: Insights From an Expert Panel
08/15/2025
Tanios Bekaii-Saab, MD, FACP; Stacey Cohen, MD; Marwan Fakih, MD; Anwaar Saeed, MD
Review a special report on the current treatment landscape and unmet needs in metastatic colorectal cancer (mCRC).
Review a special report on the current treatment landscape and unmet needs in metastatic colorectal cancer (mCRC).
Review a special report on the...
08/15/2025
Journal of Clinical Pathways
Special Report
Predictable Cost of Care Model for Treatment Decisions: Working Group Consensus Statements for Metastatic Non-Small Cell Lung Cancer
08/15/2025
Edward Arrowsmith, MD; Vishnukamal Golla, MD, MPH; Rhonda Henschel, MBA; Andrew Hertler, MD, FACP; David Jackman, MD; Gordon Kuntz; Olaf Lodbrok, MS, MBA; Carole Tremonti, RN, MBA; Lalan Wilfong, MD
The Predictable Cost of Care Working Group developed a model that can be used by various entities evaluating the impact of treatment on the total cost of care.
The Predictable Cost of Care Working Group developed a model that can be used by various entities evaluating the impact of treatment on the total cost of care.
The Predictable Cost of Care...
08/15/2025
Journal of Clinical Pathways
Special Report
Navigating the Management of Metastatic Colorectal Cancer in the Advanced Treatment Setting: Insights From an Expert Panel
06/12/2025
Tanios Bekaii-Saab, MD, FACP; Stacey Cohen, MD; Marwan Fakih, MD; Anwaar Saeed, MD
Review a special report on the current treatment landscape and unmet needs in metastatic colorectal cancer (mCRC).
Review a special report on the current treatment landscape and unmet needs in metastatic colorectal cancer (mCRC).
Review a special report on the...
06/12/2025
Journal of Clinical Pathways
Page 1
Special Report
Predictable Cost of Care Model for Treatment Decisions: Working Group Consensus Statements for Metastatic Non-Small Cell Lung Cancer
02/19/2025
Edward Arrowsmith, MD; Vishnukamal Golla, MD, MPH; Rhonda Henschel, MBA; Andrew Hertler, MD, FACP; David Jackman, MD; Gordon Kuntz; Olaf Lodbrok, MS, MBA; Carole Tremonti, RN, MBA; Lalan Wilfong, MD
The Predictable Cost of Care Working Group developed a model that can be used by various entities evaluating the impact of treatment on the total cost of care.
The Predictable Cost of Care Working Group developed a model that can be used by various entities evaluating the impact of treatment on the total cost of care.
The Predictable Cost of Care...
02/19/2025
Journal of Clinical Pathways
JCP Special Report
Recommendations for Creating an Oncology Clinical Pathways Framework Tool Based on Payer, Provider, and Patient Priorities: Findings From the 2021 Care Pathways Working Group
05/20/2022
Robin T. Zon, MD, FACP, FASCO; Gordon Kuntz; Winston Wong, PharmD
The Journal of Clinical Pathways convened the 2021 Care Pathways Working Group to identify and reconcile the different pathway drivers for each stakeholder now and five years into the future, creating a framework tool based on oncology care...
The Journal of Clinical Pathways convened the 2021 Care Pathways Working Group to identify and reconcile the different pathway drivers for each stakeholder now and five years into the future, creating a framework tool based on oncology care...
The Journal of Clinical Pathways...
05/20/2022
Journal of Clinical Pathways

HMP Global Products

Events

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2026 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Terms of Use